拉米夫定治疗慢性乙型肝炎引起的慢加急性肝衰竭患者的临床研究  

Clinical study of Lamivudine in the treatment of acute-on-chronic liver failure patients caused by hepatitis B

作　　者：尹胜平[1] 郭堑[1] 蒋茵[1] 覃平[1] 李巧于[1] 葛善飞[1] 

机构地区：[1]广西医科大学第四附属医院感染科,广西柳州545000

出　　处：《中国医药导报》2012年第17期182-183,共2页China Medical Herald

摘　　要：目的探讨对低病毒载量的慢性乙型肝炎引起的急性肝功能衰竭进行抗病毒治疗后患者的生存情况。方法将84例慢加急性肝衰竭(ACLF)患者分为观察组(低病毒载量抗病毒治疗组)和对照组(低病毒载量未抗病毒治疗组),每组各42例。两组患者均给予相同的护肝、支持、改善微循环、促进肝细胞再生、防治可能出现的并发症等方面的综合治疗。观察组在此基础上同时口服拉米夫定,100 mg/d,连续治疗2个月。结果经治疗,观察组患者血清总胆红素(TBIL)、血清白蛋白(ALB)、天门冬氨酸氨基转移酶(AST)、凝血酶原活动度(PTA)与对照组比较,差异均有统计学意义(均P<0.05)。观察组患者好转率及生存率较对照组明显增高,病死率显著降低,差异均有统计学意义(均P<0.05)。结论抗病毒治疗可提高低病毒载量的乙型肝炎引起的ACLF患者的生存率。Objective To investigate the survival situation of acute-on-chronic liver failure（ACLF） patients caused by hepatitis B with low virus volume through antiviral therapy.Methods 84 patients with ACLF were divided into observation group and control group,each group had 42 cases.Both groups were given same conventional therapy.On this basis,observation group was given Lamivudine,100 mg/d.Control group wasn＇t given antiviral therapy.All the patients were treated continuously for two months.Results There were significant difference between two groups on TBIL,ALB,AST and PTA（P 0.05）.The rate of improvement and survival in observation group were higher than those in control group,and the rate of death was lower,there were significant difference（all P 0.05）.Conclusion The antiviral therapy can improve the survival rate of ACLF patients caused by hepatitis B with low virus volume.

关 键 词：抗病毒治疗 乙型肝炎ACLF 生存率 

分 类 号：R512.62[医药卫生—内科学]